Ovarian Cancer Platinum Resistance: Mechanisms, Targets, and Personalized Treatment

Ovarian cancer is a prevalent malignant tumor, and platinum-based drugs currently serve as the first-line treatment for this disease. However, the widespread use of platinum-based drugs has led to an increase in the incidence of platinum resistance. Statistics indicate that approximately 30-50% of ovarian cancer patients develop resistance to platinum-based drugs after undergoing treatment. Hence, it is crucial to investigate platinum resistance in ovarian cancer, as comprehending the mechanisms behind it can enhance our understanding of the occurrence and progression of this disease.

At present, the development of platinum resistance is believed to involve multiple factors, such as the cell's DNA repair capacity, cell apoptosis pathway, and expression of transport proteins. Thorough research into these mechanisms can provide crucial evidence for the discovery of new treatment strategies. The emergence of platinum resistance is often associated with abnormal activation of intracellular signaling pathways. Exploring platinum resistance in ovarian cancer is advantageous in identifying new therapeutic targets and drugs. Furthermore, understanding the extent of platinum resistance in ovarian cancer is beneficial for the clinical development of personalized treatment plans. Each patient exhibits varying degrees of resistance to platinum-based drugs. Therefore, understanding the patient's resistance profile can assist doctors in selecting more suitable treatment plans and improving treatment efficacy.